Pacira BioSciences Inc. – Underwriting Agreements Watch

from DFAN14A 4 pages Yesterday, Pacira Published a 66-Page Presentation (The “Pacira Presentation”) to Make Their Case Against Doma Perpetual Capital Management LLC (“Doma Perpetual”) and Our Director Nominees. the Sheer Size of This Document Serves to Confuse Investors by Obscuring Simple Facts With an Overwhelming Amount of Information, Much of It Irrelevant or Misleading, Particularly the Information That Relates to Doma Perpetual and Our Strategy With Respect to the Company. We Value Your Time Too Much to Produce Our Own 60-Plus-Page Document to Address Every Disingenuous Representation in the Document, but We Address the Key Points Below. the Goal of Our Proxy Contest Is to Make Our Case to Shareholders That the Company’s Future Is at Stake, and Management and the Board Cannot Be Trusted to Protect Shareholders’ Interests, Because They Are More Concerned With Protecting Their Own Financial Interests

from DFAN14A 2 pages A Letter to Pacira BioSciences Shareholders From Director Nominees Christopher Dennis, MD, Mba, Fapa and Oliver Benton "Ben" Curtis III

from 8-K 48 pages 1,600,000 Shares Pacira Pharmaceuticals, Inc. Common Stock Underwriting Agreement

from 8-K 46 pages 6,000,000 Shares Pacira Pharmaceuticals, Inc. Common Stock Underwriting Agreement

from S-1/A 43 pages 6,000,000 Shares Pacira Pharmaceuticals, Inc. Common Stock Underwriting Agreement

from S-1/A 44 pages [•] Shares Pacira Pharmaceuticals, Inc. Common Stock Underwriting Agreement